European Medicines Agency 2d ago

Learn how the European Medicines Agency's PRIME (PRIority MEdicines) scheme helps accelerate the development of promising medicines for patients with unmet medical needs. In this video, Kevin Cunningham, PRIME Scientific Coordinator at EMA, and Outi Mäkki-Ikola, Finnish member of the Committee for Medicinal Products for Human Use (CHMP), discuss how PRIME provides early scientific and regulatory support to medicine developers, improves evidence generation, and enables faster assessment of innovative therapies. Discover the key benefits of PRIME and how this initiative helps bring potentially life-changing treatments to patients sooner. Learn more about the PRIME scheme here: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines